These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents. Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370 [TBL] [Abstract][Full Text] [Related]
25. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Vermeire K; Schols D Expert Opin Investig Drugs; 2005 Oct; 14(10):1199-212. PubMed ID: 16185162 [TBL] [Abstract][Full Text] [Related]
26. Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer. Nandy B; Bindu DH; Dixit NM; Maiti PK J Chem Phys; 2013 Jul; 139(2):024905. PubMed ID: 23862963 [TBL] [Abstract][Full Text] [Related]
27. HIV type 1 Gag as a target for antiviral therapy. Waheed AA; Freed EO AIDS Res Hum Retroviruses; 2012 Jan; 28(1):54-75. PubMed ID: 21848364 [TBL] [Abstract][Full Text] [Related]
28. Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections. Sepúlveda-Crespo D; Ceña-Díez R; Jiménez JL; Ángeles Muñoz-Fernández M Med Res Rev; 2017 Jan; 37(1):149-179. PubMed ID: 27518199 [TBL] [Abstract][Full Text] [Related]
29. [Membranotropic compounds and preparations affecting earlier stages of HIV-infection]. Timofeev DI; Perminova NG; Serbin AV; Timofeev IV Antibiot Khimioter; 2003; 48(2):29-41. PubMed ID: 12803048 [No Abstract] [Full Text] [Related]
30. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. Cocklin S; Gopi H; Querido B; Nimmagadda M; Kuriakose S; Cicala C; Ajith S; Baxter S; Arthos J; Martín-García J; Chaiken IM J Virol; 2007 Apr; 81(7):3645-8. PubMed ID: 17251295 [TBL] [Abstract][Full Text] [Related]
31. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors. Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386 [TBL] [Abstract][Full Text] [Related]
32. Progress in targeting HIV-1 entry. Ryser HJ; Flückiger R Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193 [TBL] [Abstract][Full Text] [Related]
33. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. Hamza A; Zhan CG J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901 [TBL] [Abstract][Full Text] [Related]
34. Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Balzarini J Lancet Infect Dis; 2005 Nov; 5(11):726-31. PubMed ID: 16253890 [TBL] [Abstract][Full Text] [Related]
35. Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view. Governa P; Manetti F Eur J Med Chem; 2022 Feb; 229():114078. PubMed ID: 34992041 [TBL] [Abstract][Full Text] [Related]
36. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432 [TBL] [Abstract][Full Text] [Related]
37. Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. Morellato-Castillo L; Acharya P; Combes O; Michiels J; Descours A; Ramos OH; Yang Y; Vanham G; Ariën KK; Kwong PD; Martin L; Kessler P J Med Chem; 2013 Jun; 56(12):5033-47. PubMed ID: 23710622 [TBL] [Abstract][Full Text] [Related]
38. Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120. Curreli F; Belov DS; Ahmed S; Ramesh RR; Kurkin AV; Altieri A; Debnath AK ChemMedChem; 2018 Nov; 13(21):2332-2348. PubMed ID: 30257071 [TBL] [Abstract][Full Text] [Related]
39. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Teixeira C; Serradji N; Maurel F; Barbault F Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340 [TBL] [Abstract][Full Text] [Related]